Hepatitis

Introduction Metabolic dysfunction–associated steatohepatitis (MASH) has become a major global liver disease burden and a central focus of therapeutic development. Despite intense pharmaceutical activity and numerous late-phase clinical trials, demonstrating meaningful histologic improvement remains challenging, partly because placebo groups frequently exhibit substantial spontaneous or treatment-associated improvement.

Problem Statement Elevated placebo response rates complicate interpretation of MASH clinical trials by reducing apparent treatment effect size and increasing the risk of failed endpoints despite biologically active therapies. The extent and determinants of placebo responses across modern MASH trials remain poorly characterized, limiting optimal trial design and endpoint selection.

Summary This large systematic review and meta-analysis demonstrates that placebo responses in MASH trials are both substantial and highly variable depending on the endpoint evaluated. Approximately one in ten placebo-treated noncirrhotic patients achieved histologic MASH resolution without fibrosis worsening, while meaningful reductions in hepatic fat content and alanine aminotransferase normalization were also frequently observed in placebo arms. Importantly, the analysis found no consistent patient or study-level factors that reliably predicted placebo response, emphasizing the inherent complexity and heterogeneity of MASH trial populations. These findings reinforce that lifestyle modification, behavioral changes triggered by trial participation and the fluctuating natural history of metabolic liver disease likely contribute significantly to placebo-associated improvement. The study also highlights that placebo effects differ across histologic, biochemical and imaging endpoints, suggesting that endpoint selection critically influences perceived therapeutic efficacy in MASH drug development. Overall, this analysis provides important context for interpreting contemporary MASH trials and underscores the need for improved trial design strategies, including more precise patient phenotyping, optimized endpoint selection and potentially longer study durations to better distinguish true drug efficacy from background placebo-associated improvement.